

**IN THE CLAIMS**

1. (withdrawn): A complex of protein-protein interactions as defined in SEQ ID Nos. 2 and 4.

2. (previously presented): A composition comprising the polynucleotides designated as SEQ ID NOS:1 and 3.

3. (withdrawn): A recombinant host cell expressing the interacting polypeptides as defined in Table 1.

4. (withdrawn): A method for selecting a modulating compound comprising:

(a) cultivating a recombinant host cell with a modulating compound on a selective medium and a reporter gene the expression of which is toxic for said recombinant host cell wherein said recombinant host cell is transformed with two vectors:

(i) wherein said first vector comprises a polynucleotide of SEQ ID No. 1 encoding a first hybrid polypeptide and a DNA bonding domain;

(ii) wherein said second vector comprises a polynucleotide of SEQ ID No. 3 encoding a second hybrid polypeptide and an activating domain that activates said toxic reporter gene when the first and second hybrid polypeptides interact;

(b) selecting said modulating compound which inhibits the growth of said recombinant host cell.

5. (withdrawn): A modulating compound obtained by the method of claim 4.

6. (currently amended): A vector comprising a polynucleotide consisting ~~essentially~~ of SEQ ID NO:1 or a polynucleotide comprising SEQ ID NO:3.

7. (withdrawn): A fragment of a polypeptide comprising SEQ ID Nos. 2 and 4.

8. (withdrawn): A variant of a polypeptide comprising SEQ ID Nos. 2 and 4.

9. (currently amended): A nucleic acid consisting of ~~comprising a fragment of the~~ sequence designated as SEQ ID NOS:1 or 3.

10. (currently amended): A variant of a polynucleotide designated as SEQ. ID NOS:1 or 3, wherein a polypeptide encoded by said polynucleotide variant binds respectively  $\beta$ TrCP or RasSF1, said variant having one type of a modification selected from the group consisting of:

a nucleotide change which is silent or which produces a conservative or non-conservative amino acid substitution, and  
a nucleotide deletion.

11. (currently amended): A recombinant host cell containing a vector comprising a polynucleotide consisting ~~essentially of~~ SEQ ID NO:1 or a vector comprising a polynucleotide comprising SEQ ID NO:3.

12. (withdrawn): A pharmaceutical composition comprising a modulating compound of Claim 5 and a pharmaceutically acceptable carrier.

13. cancelled.

14. (withdrawn): A protein chip comprising the polypeptides of Claims 7 or 8.

15. (withdrawn): A monoclonal antibody of the protein complex of claim 1.

16. (currently amended): A vector comprising a polynucleotide consisting of SEQ ID NOS:1 or a polynucleotide comprising SEQ ID NO:3.

17. cancelled.

18. (currently amended): A recombinant host cell containing a vector comprising a polynucleotide ~~comprising~~ consisting of SEQ ID NO:1 and a vector comprising a polynucleotide comprising SEQ ID NO:3.

19. cancelled.

20. (currently amended): A pharmaceutical composition for use in gene therapy, comprising a vector comprising a polynucleotide consisting essentially of SEQ ID NO:1, or a vector comprising a polynucleotide comprising SEQ ID NO:3, ~~or the vector of claim 16,~~ and a pharmaceutically acceptable carrier.

21. (new) A variant of polynucleotide designated as SEQ ID NOS:1 or 3, wherein a polypeptide encoded by said polynucleotide variant binds  $\beta$ TrCP or RasSF1 respectively, and wherein said polynucleotide variant has at least 95% homology with SEQ ID NO:1 or 99.99% homology with SEQ ID NO:3.

22. (new) A composition comprising a vector comprising a polynucleotide consisting of SEQ ID NO:1, or a vector comprising a polynucleotide comprising SEQ ID NO:3, and a carrier.